US equities
|
MU
$878.84
▼-5.63%
NVDA
$214.13
▼-1.43%
TSLA
$354.72
▼-2.13%
AAPL
$343.46
▲+0.43%
META
$709.33
▼-3.72%
MSFT
$529.05
▼-1.93%
SPCX
$146.03
▼-1.74%
AMD
$528.75
▼-5.95%
MU
$878.84
▼-5.63%
NVDA
$214.13
▼-1.43%
TSLA
$354.72
▼-2.13%
AAPL
$343.46
▲+0.43%
META
$709.33
▼-3.72%
MSFT
$529.05
▼-1.93%
SPCX
$146.03
▼-1.74%
AMD
$528.75
▼-5.95%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Lisata Therapeutics, Inc. - Common Stock
(NQ:
LSTA
)
1.030
-0.040 (-3.74%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Lisata Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
October 14, 2026
Veteran biopharma CFO brings more than 15 years of public-company financial leadership across development, approval and commercial launch; joins Audit Committee
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors
October 08, 2026
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly
October 05, 2026
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Halper Sadeh LLC is Investigating Whether BWIN, LSTA, ACVA are Obtaining Fair Deals for their Shareholders
October 04, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026
September 24, 2026
Late-breaking presentation will highlight Phase 2b clinical data for MAR001, a potential first-in-class antibody targeting ANGPTL4 designed to lower triglycerides and improve metabolic function
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement
September 17, 2026
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Provides Update Following Termination of Merger Agreement
August 04, 2026
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.
June 10, 2026
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: KalVista Pharmaceuticals, Inc. (Nasdaq – KALV), Thermon Group Holdings, Inc. (NYSE – THR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq –
May 14, 2026
From
Brodsky & Smith LLC
Via
GlobeNewswire
Halper Sadeh LLC is Investigating Whether NSA, LSTA, TALK are Obtaining Fair Deals for their Shareholders
May 12, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
Halper Sadeh LLC is Investigating Whether SILA, LSTA, ESPR are Obtaining Fair Deals for their Shareholders
May 05, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Esperion Therapeutics, Inc. (Nasdaq – ESPR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA), SkyWater Technology, Inc. (Nasdaq -
May 05, 2026
From
Brodsky & Smith LLC
Via
GlobeNewswire
Halper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their Shareholders
May 04, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
Halper Sadeh LLC is Investigating Whether TALK, UBFO, LSTA are Obtaining Fair Deals for their Shareholders
March 10, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
March 06, 2026
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Halper Sadeh LLC Reminds Shareholders of SKYT, NATH, SNCY, LSTA of the Firm’s Investigations
February 02, 2026
Shareholders should contact the firm as there may be limited time to enforce your rights
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: SkyWater Technology, Inc. (Nasdaq - SKYT), Nathan’s Famous, Inc. (Nasdaq – NATH), Lisata Therapeutics, Inc. (Nasdaq – LSTA), Sun Country Airlines Holdings, Inc.
February 02, 2026
From
Brodsky & Smith LLC
Via
GlobeNewswire
Halper Sadeh LLC Encourages NATH, PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights
January 29, 2026
Shareholders should contact the firm as there may be limited time to enforce your rights
From
Halper Sadeh LLC
Via
GlobeNewswire
Halper Sadeh LLC Encourages SKYT, NATH, LSTA Shareholders to Contact the Firm to Discuss Their Rights
January 27, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide
January 27, 2026
Lisata regains full development rights to certepetide in the Greater China Region
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
LSTA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Lisata Therapeutics, Inc. is Fair to Shareholders
January 21, 2026
From
Halper Sadeh LLC
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nathan’s Famous, Inc. (Nasdaq – NATH), Lisata Therapeutics, Inc. (Nasdaq – LSTA), Sun Country Airlines Holdings, Inc. (Nasdaq - SNCY), Ventyx Biosciences, Inc.
January 21, 2026
From
Brodsky & Smith LLC
Via
GlobeNewswire
Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer
January 21, 2026
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
November 06, 2025
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’
November 06, 2025
Annual Awards Program Recognizes Breakthrough Life Sciences & Biotechnology Innovation Around the World
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025
October 30, 2025
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent
November 04, 2025
Data from Catalent’s preclinical studies evaluating certepetide as a SMARTag® ADC payload showed both improved tumor selective penetration and efficacy
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement
October 08, 2025
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial
September 29, 2025
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 02, 2025
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
